Abstract
Mitotane is currently employed as adjuvant therapy as well as in the medical treatment of adrenocortical carcinoma (ACC), alone or in combination with chemotherapeutic agents. It was previously demonstrated that mitotane potentiates chemotherapeutic drugs cytotoxicity in cancer cells displaying chemoresistance due to P-glycoprotein (P-gp), an efflux pump involved in cancer multidrug resistance. The majority of ACC expresses high levels of P-gp and is highly chemoresistent. The aim of our study was to explore in vitro whether mitotane, at concentrations lower than those currently reached in vivo, may sensitize ACC cells to the cytotoxic effects of doxorubicin and whether this effect is due to a direct action on P-gp. NCI-H295 and SW13 cell lines as well as 4 adrenocortical neoplasia primary cultures were treated with mitotane and doxorubicin, and cell viability was measured by MTT assay. P-gp activity was measured by calcein and P-gp-Glo assays. P-gp expression was evaluated by Western blot. We found that very low mitotane concentrations sensitize ACC cells to the cytotoxic effects of doxorubicin, depending on P-gp expression. In addition, mitotane directly inhibits P-gp detoxifying function, allowing doxorubicin cytotoxic activity. These data provide the basis for the greater efficacy of combination therapy (mitotane plus chemotherapeutic drugs) on ACC patients. Shedding light on mitotane mechanisms of action could result in an improved design of drug therapy for patients with ACC.
Similar content being viewed by others
References
M. Terzolo, F. Daffara, A. Ardito, B. Zaggia, V. Basile, L. Ferrari, A. Berruti, Management of adrenal cancer: a 2013 update. J. Endocrinol. Invest. 37, 207–217 (2014)
M. Fassnacht, M. Kroiss, B. Allolio, Update in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 98, 4551–4564 (2013)
M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P.A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, G. Reimondo, E. Bollito, M. Papotti, W. Saeger, S. Hahner, A.C. Koschker, E. Arvat, B. Ambrosi, P. Loli, G. Lombardi, M. Mannelli, P. Bruzzi, F. Mantero, B. Allolio, L. Dogliotti, A. Berruti, Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med. 356, 2372–2380 (2007)
S.D. Flynn, J.R. Murren, W.M. Kirby, J. Honig, L. Kann, B.K. Kinder, P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 112, 981–986 (1992)
F.J. Sharom, ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 9, 105–127 (2008)
L. Bao, A. Haque, K. Jackson, S. Hazari, K. Moroz, R. Jetly, S. Dash, Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am. J. Pathol. 178, 838–852 (2011)
T. Stankovic, E. Marston, Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia. Srp. Arh. Celok. Lek. 136, 187–192 (2008)
M.C. Zatelli, A. Luchin, D. Piccin, F. Tagliati, A. Bottoni, C. Vignali, M. Bondanelli, E.C. Degli Uberti, Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 90, 5754–5760 (2005)
M.C. Zatelli, A. Luchin, F. Tagliati, S. Leoni, D. Piccin, M. Bondanelli, R. Rossi, E.C. Degli Uberti, Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr. Relat. Cancer 14, 1029–1038 (2007)
M.C. Zatelli, D. Molè, F. Tagliati, M. Minoia, Ambrosio, E. Degli Uberti, Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB. Cell. Oncol. 31, 457–465 (2009)
S.E. Bates, C.Y. Shieh, L.A. Mickley, H.L. Dichek, A. Gazdar, D.L. Loriaux, A.T. Fojo, Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 73, 18–29 (1991)
M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade-Brittinger, A. Lacroix, B. Jarzab, H. Sorbye, D.J. Torpy, V. Stepan, D.E. Schteingart, W. Arlt, M. Kroiss, S. Leboulleux, P. Sperone, A. Sundin, I. Hermsen, S. Hahner, H.S. Willenberg, A. Tabarin, M. Quinkler, C. de la Fouchardière, M. Schlumberger, F. Mantero, D. Weismann, F. Beuschlein, H. Gelderblom, H. Wilmink, M. Sender, M. Edgerly, W. Kenn, T. Fojo, H.H. Müller, B. Skogseid, FIRM-ACT Study Group: combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189–2197 (2012)
I. Veytsman, L. Nieman, T. Fojo, Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619–4629 (2009)
M.C. Zatelli, E. Gentilin, F. Daffara, F. Tagliati, G. Reimondo, G. Carandina, Ambrosio, M. Terzolo, E.C. Degli Uberti, Therapeutic concentrations of mitotane (o,p’-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151, 2453–2461 (2010)
E. Gentilin, F. Tagliati, M. Terzolo, M. Zoli, M. Lapparelli, M. Minoia, M.R. Ambrosio, E.C. degli Uberti, M.C. Zatelli, Mitotane reduces human and mouse ACTH-secreting pituitary cells viability and function. J. Endocrinol. 218, 275–285 (2013)
E. Gentilin, D. Molè, T. Gagliano, M. Minoia, M.R. Ambrosio, E.C. Degli Uberti, M.C. Zatelli, Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines. Reprod. Toxicol. 45, 71–76 (2014)
M.C. Zatelli, R. Rossi, E.C. Degli Uberti, Androgen influences Transforming Growth Factor Beta1 (TGF b1) gene expression in human adrenocortical cells. J. Clin. Endocrinol. Metab. 85, 847–852 (2000)
R. Rossi, M.C. Zatelli, A. Valentini, P. Cavazzini, F. Fallo, L. del Senno, E.C. degli Uberti, Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. J. Endocrinol. 159, 373–380 (1998)
M.C. Zatelli, D. Piccin, F. Tagliati, A. Bottoni, A. Luchin, C. Vignali, A. Margutti, M. Bondanelli, G.C. Pansini, Pelizzo, M.D. Culler, E.C. Degli Uberti, Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J. Clin. Endocrinol. Metab. 91, 2218–2224 (2006)
M.C. Zatelli, F. Tagliati, D. Piccin, J.E. Taylor, M.D. Culler, M. Bondanelli, E.C. Degli Uberti, Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun. 29, 828–834 (2002)
T. Gagliano, M. Bellio, E. Gentilin, D. Molè, F. Tagliati, M. Schiavon, N.G. Cavallesco, L.G. Andriolo, M.R. Ambrosio, F. Rea, E. degli Uberti, M.C. Zatelli, mTOR, p70S6 K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3 K/mTOR inhibitors in human bronchial carcinoids. Endocr. Relat. Cancer 20, 463–475 (2013)
F. Tagliati, M.C. Zatelli, A. Bottoni, D. Piccin, A. Luchin, M.D. Culler, E.C. degli Uberti, Role of complex Cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. Endocrinology 147, 3530–3538 (2006)
K. Fujimoto, G. Fujii, M. Mutoh, M. Yasunaga, H. Tanaka, M. Wada, Suppression of intestinal polyp development in Apc(Min/+) mice through inhibition of P-glycoprotein using verapamil. Eur. J. Cancer Prev. 22, 8–10 (2013)
R.A. Decker, P. Elson, T.F. Hogan, D.L. Citrin, D.W. Westring, T.K. Banerjee, K.W. Gilchrist, J. Horton, Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery. 110, 1006–1013 (1991)
C. Hantel, S. Jung, T. Mussack, M. Reincke, F. Beuschlein, Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. Endocr. Relat. Cancer 21, 383–394 (2014)
R. Villa, L. Orlandi, A. Berruti, L. Dogliotti, N. Zaffaroni, Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int. J. Oncol. 14, 133–138 (1999)
G. Poli, D. Guasti, E. Rapizzi, R. Fucci, L. Canu, A. Bandini, N. Cini, D. Bani, M. Mannelli, M. Luconi, Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells. Endocr. Relat. Cancer 20, 537–550 (2013)
P.M. van Koetsveld, G. Vitale, R.A. Feelders, M. Waaijers, D.M. Sprij-Mooij, R.R. de Krijger, E.J. Speel, J. Hofland, S.W. Lamberts, W.W. de Herder, L.J. Hofland, Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr. Relat. Cancer 20, 443–454 (2013)
M.C. Zatelli, R. Rossi, L. del Senno, E.C. Degli Uberti, Role of transforming growth factor beta 1 (TGF beta 1) in mediating androgen-induced growth inhibition in human adrenal cortex in vitro. Steroids 63, 243–245 (1998)
M.C. Zatelli, M. Minoia, C. Martini, F. Tagliati, Ambrosio, M. Schiavon, M. Buratto, F. Calabrese, F. Calabrese, E. Gentilin, G. Cavallesco, L. Berdondini, F. Rea, E.C. Degli Uberti, Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr. Relat. Cancer 28, 719–729 (2010)
M.C. Zatelli, M. Minoia, C. Filieri, F. Tagliati, M. Buratto, Ambrosio, M. Lapparelli, M. Scanarini, E.C. Degli Uberti, Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 95, 968–976 (2010)
D.R. Barpe, D.D. Rosa, P.E. Froehlich, Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur. J. Pharm. Sci. 41, 458–463 (2010)
E. Bello-Reuss, S. Ernest, O.B. Holland, M.R. Hellmich, Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am. J. Physiol. Cell Physiol. 278, 1256–1265 (2000)
K. Ueda, D.P. Clark, C.J. Chen, I.B. Roninson, M.M. Gottesman, I. Pastan, The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 262, 505–508 (1987)
M. Dean, The Human ATP-Binding Cassette (ABC) Transporter Superfamily (National Library of Medicine, US, 2002)
H.R. Haak, A.P. van Seters, A.J. Moolenaar, G.J. Fleuren, Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur. J. Cancer 29A, 1036–1038 (1993)
S.D. Flynn, J.R. Murren, W.M. Kirby, J. Honig, L. Kann, B.K. Kinder, P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 112, 981–986 (1992)
J. Abraham, S. Bakke, A. Rutt, B. Meadows, M. Merino, R. Alexander, D. Schrump, D. Bartlett, P. Choyke, R. Robey, E. Hung, S.M. Steinberg, S. Bates, T. Fojo, A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94, 2333–2343 (2002)
F. Daffara, S. De Francia, G. Reimondo, B. Zaggia, M. Arosio, F. Porpiglia, M. Volante, A. Termine, F. Di Carlo, L. Dogliotti, A. Angeli, A. Berruti, M. Terzolo, Prospective evaluation of mitotane toxicity in adrenalcortical cancer patients treated adjuvantly. Endocr. Relat. Cancer 15, 1043–1053 (2008)
M. Lotrionte, G. Biondi-Zoccai, A. Abbate, G. Lanzetta, F. D’Ascenzo, V. Malavasi, M. Peruzzi, G. Frati, G. Palazzoni, Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am. J. Cardiol. 112, 1980–1984 (2013)
D. Ferone, C. Pivonello, G. Vitale, M.C. Zatelli, A. Colao, R. Pivonello, Molecular basis of pharmacological therapy in Cushing’s disease. Endocrine 46, 181–198 (2014)
Acknowledgments
This work was supported by grants from the Italian Ministry of Education, Research and University (FIRB RBAP11884 M, RBAP1153LS, 2010TYCL9B_002), Fondazione Cassa di Risparmio di Ferrara, and Associazione Italiana per la Ricerca sul Cancro (AIRC) in collaboration with Laboratorio in rete del Tecnopolo “Tecnologie delle terapie avanzate” (LTTA) of the University of Ferrara.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gagliano, T., Gentilin, E., Benfini, K. et al. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. Endocrine 47, 943–951 (2014). https://doi.org/10.1007/s12020-014-0374-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0374-z